High-Efficacy Therapy Strategies for Aggressive MS: Patricia Coyle, MD

WATCH TIME: 3 minutes | Captions are auto-generated and may contain errors.

“There is accumulating data that indicates that the best results to avoid long-term disability are probably to use a high-efficacy agent early on in relapsing MS.”

The 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 27-29 in Charlotte, North Carolina, marks the organization’s 40th annual gathering. Recognized as one of the leading meetings in the MS field, the conference brings together clinicians, researchers, and advocates to discuss the latest advances in MS and related neurologic disorders, with a focus on emerging science, clinical care, and improving patient outcomes.

Throughout the 3-day meeting, attendees can explore developments in MS diagnosis, disease-modifying therapies, and multidisciplinary patient care. The program features sessions on topics such as rehabilitation, biomarkers, access to care, and clinical research, while fostering collaboration and education aimed at helping healthcare professionals address the evolving needs of people living with MS.

Among the clinicians presenting at the 2026 CMSC Annual Meeting was Patricia Coyle, MD, professor of neurology and director of the Stony Brook MS Comprehensive Care Center in New York. Coyle, a recognized expert in the MS field, presented recently completed late-breaking data comparing 2 MS treatments in a subgroup analysis. The study, titled “Efficacy and Safety of Ofatumumab Versus Teriflunomide in Participants with Highly Active Relapsing Multiple Sclerosis: Subgroup Analysis from ASCLEPIOS I/II,” evaluated high-efficacy therapy in patients with highly active relapsing MS.

During the meeting, NeurologyLive sat down with Coyle to discuss the findings. During the conversation, she outlined how the analysis focused on a subgroup of patients with more aggressive disease characteristics and reviewed the broader implications of the findings for relapse control, MRI outcomes, and long-term disease management. The discussion also touched on the evolving role of early high-efficacy treatment strategies in relapsing MS and what the results may mean for future clinical decision-making.

Click here for more CMSC 2026 coverage.